European Heart Journal vs Hepatology: Which Journal Should You Choose?
European Heart Journal is the better first target for broad cardiovascular papers. Hepatology is stronger for liver-disease work with real mechanistic, translational, or clinical hepatology consequence.
Journal fit
See whether this paper looks realistic for European Heart Journal.
Run the Free Readiness Scan with European Heart Journal as your target journal and see whether this paper looks like a realistic submission.
European Heart Journal at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 35.6 puts European Heart Journal in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~10% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: European Heart Journal takes ~~20 days. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
European Heart Journal vs Hepatology at a glance
Use the table to see where the journals diverge before you read the longer comparison. The right choice usually comes down to scope, editorial filter, and the kind of paper you actually have.
Question | European Heart Journal | Hepatology |
|---|---|---|
Best fit | European Heart Journal is the European Society of Cardiology's flagship publication and. | Hepatology is THE liver journal. If you study any aspect of liver biology or disease,. |
Editors prioritize | European scope with global relevance | Liver-specific expertise and insight |
Typical article types | Clinical Research, Basic Science | Original Research, Brief Communication |
Closest alternatives | Circulation, Journal of the American College of Cardiology | Journal of Hepatology, Gut |
Quick answer: This comparison becomes real when a manuscript sits between cardiovascular medicine and liver disease. If the paper is fundamentally about cardiovascular consequence, risk, prevention, or cardiology management, European Heart Journal is usually the better first target. If the manuscript is fundamentally about liver disease, hepatology care, liver biology, or translational hepatology, Hepatology is usually the better home.
If the paper is fundamentally about cardiovascular consequence, risk, prevention, or cardiology management, European Heart Journal is usually the better first target. If the manuscript is fundamentally about liver disease, hepatology care, liver biology, or translational hepatology, Hepatology is usually the better home.
The problem is that some of the most interesting modern papers don't stay neatly inside one specialty. MASLD and cardiometabolic disease, cirrhosis-related cardiovascular complications, transplant-related outcomes, and inflammatory vascular risk can all create a real EHJ-versus-Hepatology decision.
That doesn't mean the broader brand will work, and it won't help if the manuscript still speaks mostly to the specialty you're actually writing for.
Quick verdict
European Heart Journal is for top cardiovascular papers that happen to involve liver disease. Hepatology is for top liver-disease papers that happen to involve cardiovascular consequence.
That distinction sounds small, but it's the entire decision.
Journal fit
Ready to find out which journal fits? Run the scan for European Heart Journal first.
Run the scan with European Heart Journal as the target. Get a fit signal that makes the comparison concrete.
Head-to-head comparison
Metric | European Heart Journal | Hepatology |
|---|---|---|
2024 JIF | 35.6 | Top-field hepatology journal |
Quartile | Q1 | Q1 |
Estimated acceptance rate | Around 10% | Not firmly quantified |
Estimated desk rejection | Very high for narrow or specialty-bound studies | High for liver papers without broad field consequence |
Typical first decision | Fast editorial triage, then selective peer review | Editorial screening begins quickly after submission |
Submission system | ScholarOne through Oxford Academic | ScholarOne through Wiley / AASLD |
Strongest fit | Broad cardiovascular consequence | Liver-focused work with mechanistic, translational, or clinical hepatology importance |
The main editorial difference
EHJ wants the result to matter across cardiology. Hepatology wants the result to matter across liver disease.
That's the cleanest decision rule.
EHJ's editorial guidance emphasize cardiovascular breadth, ESC relevance, and field-level consequence. Hepatology's editorial guidance emphasize unmistakable liver focus, mechanistic or translational depth, and the need to connect clearly to real hepatology questions.
If your manuscript feels most persuasive when written in cardiology language, EHJ is usually closer. If the paper only really comes alive when written in liver-disease language, Hepatology is usually the better call.
Where European Heart Journal wins
EHJ wins when the cardiovascular story is the central story.
That usually means:
- cardiovascular outcomes are the primary endpoints that matter
- the practical audience is cardiologists
- the liver or metabolic context is important, but not the main home field
- the paper could plausibly influence broad cardiovascular interpretation or management
Examples:
- MASLD studies where the true consequence is cardiovascular-risk prediction or management
- cirrhosis-related hemodynamic or arrhythmia work when cardiology practice is the key audience
- cross-specialty registry studies where the main implication is for cardiovascular care
EHJ's editorial guidance also make clear that the journal wants more than a specialty intersection. It wants field-wide cardiovascular significance.
Where Hepatology wins
Hepatology wins when the liver story remains central.
That includes:
- liver-disease studies where cardiovascular outcomes are important but still secondary to hepatology understanding
- mechanistic work in liver disease with translational value
- MASLD, fibrosis, inflammation, cirrhosis, transplantation, or liver-oncology work that belongs naturally to hepatology readers
- manuscripts where the best conversation is among hepatologists, not general cardiologists
Hepatology's editorial guidance keep stressing a strong liver identity. That matters here because many crossover papers are attractive scientifically but still have a very obvious home field once you strip away the prestige question.
Hepatology expects unmistakable liver focus
Hepatology submission's editorial guidance is explicit that the journal wants work that AASLD editors can connect immediately to real hepatology problems. If the manuscript needs too much cardiology framing to explain itself, that's a clue it may belong elsewhere.
EHJ expects broader cardiovascular consequence
The EHJ material repeatedly emphasizes general cardiovascular relevance and strong consequences for cardiology readers. A liver-context paper can fit there, but only if the cardiovascular implication is broad enough.
Hepatology can carry deeper mechanistic liver narratives
That matters because some cardio-liver papers are really about liver biology, metabolic disease, or disease-pathway interpretation. Those papers often get weaker, not stronger, when stripped down into a general cardiology frame.
EHJ won't rescue a niche liver paper
A strong liver paper with some cardiovascular spillover doesn't become an EHJ paper just because heart-related outcomes are present. The cardiology consequence still has to dominate.
Choose European Heart Journal if
- the paper is fundamentally cardiovascular
- cardiologists are the main audience
- the main implication is about cardiovascular risk, management, or outcomes
- the manuscript feels strongest when written as a cardiology paper
That's the EHJ lane.
Choose Hepatology if
- the paper is fundamentally about liver disease
- hepatologists are the main audience
- the manuscript depends on liver-specific context to be convincing
- the strongest consequence is inside hepatology, even if cardiovascular outcomes are important
That's the Hepatology lane.
MASLD and cardiometabolic overlap
This is probably the most common real overlap. If the paper is mainly about cardiovascular risk or cardiovascular outcome prediction, EHJ becomes more plausible. If it's mainly about liver disease progression, liver-pathway biology, or hepatology management, Hepatology is usually the cleaner fit.
Cirrhosis and cardiovascular complications
These papers can sound broad, but the audience question still decides the case. If the work is mainly for hepatologists dealing with cirrhotic physiology, portal complications, or liver-specific risk, Hepatology usually wins. If the work should change how cardiologists interpret or manage patients with major cardiovascular implications, EHJ gets stronger.
Transplant and outcome papers
Again, ask who needs the result most. If the result primarily informs transplant-hepatology decision-making, Hepatology is likely better. If it primarily informs cardiovascular interpretation across broader practice, EHJ becomes more realistic.
The cascade strategy
This can be a real cascade, but only when the paper was mispositioned.
A manuscript rejected by EHJ can move to Hepatology if the work is genuinely liver-led and the rejection reflects insufficient breadth for general cardiology rather than weak science.
The reverse route is less common. A paper rejected by Hepatology because it lacks a sufficiently strong liver identity usually doesn't become an EHJ paper unless the cardiovascular consequence was truly under-framed.
EHJ punishes organ-specific framing that never becomes broad cardiology
If the manuscript remains heavily liver-defined all the way through, EHJ often looks like the wrong room.
Hepatology punishes papers that borrow liver context but aren't really hepatology papers
If the manuscript only touches liver disease but the result isn't actually about a hepatology question, the fit weakens quickly.
EHJ punishes inflated claims of breadth
Editors can usually tell when a cross-specialty paper is trying to sound more generally cardiovascular than it really is.
Hepatology punishes thin translational payoff
The journal can take mechanistic and translational work, but it still wants clear field-level importance and a reason hepatologists should care.
What a strong first page looks like in each journal
A strong EHJ first page makes the cardiovascular consequence obvious before the liver context becomes detailed.
A strong Hepatology first page makes the liver-disease consequence obvious before any cardiovascular crossover detail takes over the narrative.
If only one of those first pages feels natural, that usually tells you the better journal.
Another practical clue
Try finishing one of these sentences:
- "this changes what cardiologists should do or how they stratify risk" points toward European Heart Journal
- "this changes what hepatologists should do or how they interpret liver disease" points toward Hepatology
That sentence test is basic, but it usually reveals the true center of gravity.
A realistic decision framework
Send to European Heart Journal first if:
- the manuscript is fundamentally cardiovascular
- the practical readership is cardiology
- cardiovascular consequence is the main reason the paper matters
- liver context supports the story, but doesn't define it
Send to Hepatology first if:
- the manuscript is fundamentally liver focused
- the practical readership is hepatology
- liver biology or liver care is the main reason the paper matters
- cardiovascular outcomes are important, but still sit inside a hepatology story
Bottom line
Choose European Heart Journal for cardio-liver papers whose real consequence is broad cardiovascular medicine. Choose Hepatology for papers whose real consequence sits in liver disease, translational hepatology, or hepatology care.
That's usually the smarter first-target strategy.
If you want a fast outside read on whether your manuscript is truly broad cardiology or still a liver-first paper, a EHJ vs. Hepatology scope check is a useful first filter.
Frequently asked questions
Submit to European Heart Journal first if the manuscript is mainly a cardiovascular paper and cardiologists are the main audience. Submit to Hepatology first if the paper is fundamentally about liver disease, liver biology, or hepatology care, even when cardiovascular outcomes are important.
Only on boundary topics such as MASLD and cardiovascular risk, cirrhosis-related cardiovascular complications, transplantation and cardiac outcomes, or vascular consequences of liver disease. Most papers are more clearly one field than the other.
European Heart Journal wants broad cardiovascular consequence across cardiology. Hepatology wants liver-focused manuscripts with mechanistic, translational, or clinical importance that matter broadly across hepatology.
Yes, if the work is genuinely liver-led and the main reason for rejection was that the paper was too specialty-defined for a flagship general cardiology journal. The manuscript still has to meet Hepatology's own high bar for liver-field consequence.
Sources
Final step
See whether this paper fits European Heart Journal.
Run the Free Readiness Scan with European Heart Journal as your target journal and get a manuscript-specific fit signal before you commit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
Compare alternatives
Supporting reads
Conversion step
See whether this paper fits European Heart Journal.
Anthropic Privacy Partner. Zero-retention manuscript processing.